Roche Aktie News

Die beiden großen Schweizer Pharmaunternehmen Roche und Novartis hatten kurzfristig mit etwas Gegenwind zu kämpfen, sollten langfristig jedoch gut aufgestellt sein.

MONTREAL--(BUSINESS WIRE)--Lomiko Metals Inc. (TSX.V: LMR) (“Lomiko” or the “Company”) announces exploration results from the spring program at the Ruisseau graphite prospect and plans for the summer/fall exploration and drilling program anticipated in November 2025. Gordana Slepcev, CEO, President, and Director, stated: “We're thrilled to advance our work on the Ruisseau graphite prospect foll...

Basel, 30 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Johannes (Hans) Clevers (1957), M.D., Ph.D., Head of Roche Pharma Research and Early Development (pRED) and member of the enlarged Corporate Executive Committee will be retiring from Roche. Hans Clevers joined the Roche Board of Directors in 2019 and then was appointed Head of Roche pRED in March 2022.

President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy. But will it work?

Roche Holding AG (OTCQX:RHHBY) Virtual Hematology Investor Conference Call June 23, 2025 1:00 PM ET Company Participants Bruno Eschli - Head of Investor Relations Charles S. Fuchs - Global Head of Oncology & Hematology Drug Development—Genentech & Roche Daud Chaudry - Corporate Participant Conference Call Participants Colin Peter White - UBS Investment Bank, Research Division David Paul Evans -...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio® (mosunetuzumab-axgb) administered subcutaneously in combination with Polivy® (polatuzumab vedotin-piiq) demonstrated a clinically meaningful and statistically significant improvement in its prima...

Basel, 20 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today results from the phase III SUNMO [NCT05171647] study showing Lunsumio® (mosunetuzumab) administered subcutaneously in combination with Polivy® (polatuzumab vedotin) demonstrated a clinically meaningful and statistically significant improvement in its primary endpoints of progression-free survival (PFS) and objective respon...

Zwischen Sicherheitswarnung und Pipeline-Hoffnung: Wie Analysten die Chancen und Risiken beim Schweizer Roche-Konzern aktuell bewerten.